Novel treatment strategies for soft tissue sarcoma

Kasper, Bernd; Gil, Thierry; Gebhart, Michaël; Awada, Ahmad

doi:10.1016/j.critrevonc.2006.11.008

Cited by 32 publications

(27 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This information will contribute valuable knowledge that may enhance our ability to successfully treat high-risk patients. Understanding important aspects of tumor biology will be fundamental to developing future strategies of targeted therapy [89]. Such mechanisms may include resistance to chemotherapy via several mechanisms, including drug transporting proteins [90], alternative pathways to cell death, such as death receptor ligands [91] and receptor tyrosine kinase inhibitors, and the tumor-initiated protection against apoptosis that is mediated by P-glycoprotein and the MDR-associated protein family (e.g., MRP1) [92].…”

Section: Targeted Therapymentioning

confidence: 99%

Prognostic factors in soft-tissue sarcomas: what have we learnt?

Choong¹,

Rüdiger

2008

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Section: Targeted Therapymentioning

confidence: 99%

Prognostic factors in soft-tissue sarcomas: what have we learnt?

Choong¹,

Rüdiger

2008

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

“…In the last decade experimental and clinical oncologists have started to develop anticancer drugs that have been designed to inhibit specific targets relevant to cancer cell growth, survival and angiogenesis [48,49]. Table 2: Plant-derived natural NF-kB inhibitors Figure 1.…”

Section: Discussionmentioning

confidence: 99%

Modulation of Gene Transcription by Natural Products - A Viable Anticancer Strategy

D’Incalci

Brunelli²,

Marangon³

et al. 2007

CPD

View full text Add to dashboard Cite

Drug design based on the structure of specific enzymes playing a role in carcinogenesis, e.g. tyrosine kinases, has been successful at identifying novel effective anticancer drugs. In contrast, no success has been achieved in drug design attempts, in which transcription factors or DNA-transcription factor complexes involved in the pathogenesis of human neoplasms were targeted. This failure is probably due to the fact that the mechanism of transcription regulation is probably too complex and still too inadequately understood to be a suitable target for drug design.It seems plausible that the high selectivity of some human tumors to some DNAinteractive anticancer drugs, e.g. cisplatin, is related to an effect on the transcription of genes that are crucial for those tumors. In this article we propose that some natural products have evolutionarily evolved to exert highly specialized functions, including modulation of the transcriptional regulation of specific genes. We discuss in detail the marine natural product Yondelis (Trabectedin, ET-743) that is effective against some soft tissue sarcoma, possibly because it interferes with the aberrant transcription mechanism in these tumors. In addition we highlight the existing evidence that many different natural products are effective inhibitors of NF-kB, a transcription factor that plays a crucial role in inflammation and cancer, indicating that some of these compounds might possess antitumor properties. We propose that large-scale characterization of natural products acting as potential modulators of gene transcription is a realistic and attractive approach to discover compounds therapeutically effective against neoplastic diseases characterized by specific aberrations of transcriptional regulation.3

show abstract

“…The typical result is that these cells survive treatment and proliferate as a more aggressive tumor. Furthermore, there are limited chemotherapeutic options, particularly if treatment with doxorubicin and ifosfamide fail, for example, the response rate in sarcomas is 35% (Kasper et al 2007;Von Mehren 2003;Clark et al 2005). Treatment is further complicated by side eVects such as myelosuppression, cardiotoxicity, neurotoxicity and nephrotoxicity.…”

Section: Introductionmentioning

confidence: 98%

“…Hence, it can be said that a new approach is required for tackling these issues. The recent shift away from broad-spectrum chemotherapy to molecular targeted therapy has been seen in the treatment of all cancers, including breast, lung, prostate, pancreatic, bowel carcinomas and sarcomas (Hewish et al 2009;Kasper et al 2007).…”

Section: Introductionmentioning

confidence: 99%